orantinib has been researched along with Adenocarcinoma Of Kidney in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fukata, S; Iiyama, T; Inoue, K; Karashima, T; Kawada, C; Kurabayashi, A; Shuin, T | 1 |
1 other study(ies) available for orantinib and Adenocarcinoma Of Kidney
| Article | Year |
|---|---|
Blockade of the vascular endothelial growth factor-receptor 2 pathway inhibits the growth of human renal cell carcinoma, RBM1-IT4, in the kidney but not in the bone of nude mice.
Topics: Animals; Bone and Bones; Carcinoma, Renal Cell; Cell Proliferation; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Humans; Indoles; Kidney; Kidney Neoplasms; Loss of Heterozygosity; Mice; Mutation; Oxindoles; Propionates; Pyrroles; Radiography; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; von Hippel-Lindau Disease; Von Hippel-Lindau Tumor Suppressor Protein | 2007 |